A Pilot Evaluation of the Safety and Efficacy of Topographically Customized Corneal Cross Linking for the Treatment of Myopia.
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Riboflavin (Primary)
- Indications Myopia
- Focus Therapeutic Use
- Acronyms CXLMyopie
- 30 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 20 Sep 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 20 Sep 2018 Status changed from recruiting to active, no longer recruiting.